RNS Number : 6288T
Diaceutics PLC
24 June 2024
 

Diaceutics - Result of Annual General Meeting

 

Belfast and London, 24 June 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

 

Resolution

For (excluding at Chair's discretion)

Against

Total votes cast

Withheld



Number of votes

%

Number of votes

%

 

Number of votes

1

Ordinary resolution to receive and consider the 2023 Financial Statements

51,263,551

100.00%

0

0.00%

51,263,551

 

Nil

 

2

Ordinary resolution to approve the directors' remuneration report

49,660,883

99.65%

172,168

0.35%

51,263,551

 

1,439,500

3

Ordinary resolution to re-elect Graham Paterson as a director

51,263,551

100%

0

0.00%

51,263,551

Nil

4

Ordinary resolution to re-elect Deborah Davis as a director

47,743,288

100%

0

0.00%

51,263,551

3,520,263

5

Ordinary resolution to re-elect Ryan Keeling as a director

51,263,551

100%

0

0.00%

51,263,551

Nil

6

Ordinary resolution to re-appoint Ernst & Young as auditors

51,261,890

99.99%

1,661

0.01%

51,263,551

 

Nil

7

Ordinary resolution to authorise the directors to determine the remuneration of the auditors

51,263,551

100.00%

0

0.00%

51,263,551

 

Nil

 

8

Ordinary resolution to authorise the directors to allot shares

51,263,551

100.00%

0

0.00%

51,263,551

 

Nil

 

9

Special resolution to authorise the directors to issue shares for cash

 

51,256,305

99.9%

7,246

0.01%

51,263,551

 

Nil

10

Special resolution to authorise the directors to purchase own shares

51,263,551

100%

0

0.00%

51,263,551

Nil

11

Special resolution to cancel the amount standing to the credit of the Company's share premium account

51,263,551

100%

0

0.00%

51,263,551

Nil

Concerning Resolution 11 and the proposed reduction of capital, it was previously announced in the notes to the Notice of Annual General Meeting that the initial directions hearing was anticipated to take place on 3 July 2024, and that the final Court hearing to confirm the capital reduction was anticipated to take place on 16 July 2024. The Company notes that these dates have since changed. Diaceutics will confirm the updated timing in due course.

 

Enquiries: 

 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 



Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 


Nick Harland 


Kate Hanshaw




Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde

Kinvara Verdon

Kieran Breheny 

diaceutics@almastrategic.com



 

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGMZGZVZDDGDZM
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Diaceutics
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Diaceutics